c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutation.

摘要: Although EGFR-targeted therapy has been beneficial to colorectal cancer patients, several studies have showed this clinical benefit was restricted patients with wild-type KRAS exon 2 cancer. Therefore, it is crucial explore efficient treatment strategies in mutations. c-Met an emerging target for the development of therapeutics against In study, we first used SW620 cell line, which activating mutation, generate a stable line conditional regulation c-Met, essential gene growth and oncogene. Using approach, evaluated benefits combined c-Met-targeted irradiation or chemical agents. observed that proliferation migration cells were reduced by induction shRNA. Furthermore, knockdown enhanced anti-proliferative effects 5-FU Taxol but not cisplatin, irinotecan sorafenib. These enhancements also another colon HCT-116, mutation. The response knockdown. This method obtained data might important implications exploring combinatory targeted therapies conventional medications. Moreover, suggested combination chemotherapy be effective strategy harboring